Home > Research > Publications & Outputs > VP2 virus-like particles elicit protective immu...

Electronic data

  • VP2_Virus_Like_Particles_elicit_protective_immunity_against_duckling_short_beak_and_dwarfism_syndrome_in_duck_and_chicks

    Rights statement: This is the peer reviewed version of the following article: Xiao, S, Wang, S, Jiang, D, et al. VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks. Transbound Emerg Dis. 2022; 69: 570– 578. doi: 10.1111/tbed.14021 which has been published in final form at https://onlinelibrary.wiley.com/doi/10.1111/tbed.14021. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving.

    Accepted author manuscript, 297 KB, PDF document

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks. / Xiao, S.; Wang, S.; Jiang, D. et al.

In: Transboundary and Emerging Diseases, Vol. 69, No. 2, 31.03.2022, p. 570-578.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Xiao, S, Wang, S, Jiang, D, Cheng, X, Zhu, X, Lin, F, Yu, B, Dong, H, Wang, X, Munir, M, Rohaim, MA, Chen, S & Chen, S 2022, 'VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks', Transboundary and Emerging Diseases, vol. 69, no. 2, pp. 570-578. https://doi.org/10.1111/tbed.14021

APA

Xiao, S., Wang, S., Jiang, D., Cheng, X., Zhu, X., Lin, F., Yu, B., Dong, H., Wang, X., Munir, M., Rohaim, M. A., Chen, S., & Chen, S. (2022). VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks. Transboundary and Emerging Diseases, 69(2), 570-578. https://doi.org/10.1111/tbed.14021

Vancouver

Xiao S, Wang S, Jiang D, Cheng X, Zhu X, Lin F et al. VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks. Transboundary and Emerging Diseases. 2022 Mar 31;69(2):570-578. Epub 2021 Feb 21. doi: 10.1111/tbed.14021

Author

Xiao, S. ; Wang, S. ; Jiang, D. et al. / VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks. In: Transboundary and Emerging Diseases. 2022 ; Vol. 69, No. 2. pp. 570-578.

Bibtex

@article{722d1769deb24e1d9ab1d3ad08212533,
title = "VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks",
abstract = "Duckling short beak and dwarfism syndrome virus (SBDSV), an emerging goose parvovirus, has caused short beak and dwarfism syndrome (SBDS) in Chinese duck flocks since 2015. Presently, there is no commercial vaccine against SBDS. In the present study, a virus-like particle (VLP)-based candidate vaccine was developed against this disease. A baculovirus expression system was used to express the SBDSV VP2 protein in Sf9 cells. Immunofluorescence assay, sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting were used to confirm protein expression. Furthermore, transmission electron microscopy was used to observe the formation of VLPs. VLPs were formulated into an oil-adjuvanted maternal vaccine to evaluate humoral responses in breeding ducks via latex particle agglutination inhibition assay (LPAI) and microneutralization assay. The offspring were challenged with SBDSV to test the protective efficacy. A single dose of SBDSV was able to induce the high level of LPAI antibodies in ducks, with LPAI and neutralization peak titres of 4.9 ± 1.20 log2 and 7.1 ± 1.20 log2, respectively, at 4 weeks post-vaccination (wpv). The average LPAI titre of yolk antibodies in duck eggs receiving 2 doses (first and boost doses) of the vaccine was 5.3 ± 1.09 log2 at 4 weeks post-boost. The protective efficacy of the maternal vaccine was 87.5%–100%. These results indicate that SBDSV VLPs can be a promising vaccine candidate for controlling SBDS. ",
keywords = "Cherry Valley ducks, duckling short beak and dwarfism syndrome, protective immunity, virus-like particle",
author = "S. Xiao and S. Wang and D. Jiang and X. Cheng and X. Zhu and F. Lin and B. Yu and H. Dong and X. Wang and M. Munir and M.A. Rohaim and S. Chen and Shaoying Chen",
note = "This is the peer reviewed version of the following article: Xiao, S, Wang, S, Jiang, D, et al. VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks. Transbound Emerg Dis. 2022; 69: 570– 578. doi: 10.1111/tbed.14021 which has been published in final form at https://onlinelibrary.wiley.com/doi/10.1111/tbed.14021. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving. ",
year = "2022",
month = mar,
day = "31",
doi = "10.1111/tbed.14021",
language = "English",
volume = "69",
pages = "570--578",
journal = "Transboundary and Emerging Diseases",
issn = "1865-1674",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks

AU - Xiao, S.

AU - Wang, S.

AU - Jiang, D.

AU - Cheng, X.

AU - Zhu, X.

AU - Lin, F.

AU - Yu, B.

AU - Dong, H.

AU - Wang, X.

AU - Munir, M.

AU - Rohaim, M.A.

AU - Chen, S.

AU - Chen, Shaoying

N1 - This is the peer reviewed version of the following article: Xiao, S, Wang, S, Jiang, D, et al. VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks. Transbound Emerg Dis. 2022; 69: 570– 578. doi: 10.1111/tbed.14021 which has been published in final form at https://onlinelibrary.wiley.com/doi/10.1111/tbed.14021. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving.

PY - 2022/3/31

Y1 - 2022/3/31

N2 - Duckling short beak and dwarfism syndrome virus (SBDSV), an emerging goose parvovirus, has caused short beak and dwarfism syndrome (SBDS) in Chinese duck flocks since 2015. Presently, there is no commercial vaccine against SBDS. In the present study, a virus-like particle (VLP)-based candidate vaccine was developed against this disease. A baculovirus expression system was used to express the SBDSV VP2 protein in Sf9 cells. Immunofluorescence assay, sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting were used to confirm protein expression. Furthermore, transmission electron microscopy was used to observe the formation of VLPs. VLPs were formulated into an oil-adjuvanted maternal vaccine to evaluate humoral responses in breeding ducks via latex particle agglutination inhibition assay (LPAI) and microneutralization assay. The offspring were challenged with SBDSV to test the protective efficacy. A single dose of SBDSV was able to induce the high level of LPAI antibodies in ducks, with LPAI and neutralization peak titres of 4.9 ± 1.20 log2 and 7.1 ± 1.20 log2, respectively, at 4 weeks post-vaccination (wpv). The average LPAI titre of yolk antibodies in duck eggs receiving 2 doses (first and boost doses) of the vaccine was 5.3 ± 1.09 log2 at 4 weeks post-boost. The protective efficacy of the maternal vaccine was 87.5%–100%. These results indicate that SBDSV VLPs can be a promising vaccine candidate for controlling SBDS.

AB - Duckling short beak and dwarfism syndrome virus (SBDSV), an emerging goose parvovirus, has caused short beak and dwarfism syndrome (SBDS) in Chinese duck flocks since 2015. Presently, there is no commercial vaccine against SBDS. In the present study, a virus-like particle (VLP)-based candidate vaccine was developed against this disease. A baculovirus expression system was used to express the SBDSV VP2 protein in Sf9 cells. Immunofluorescence assay, sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting were used to confirm protein expression. Furthermore, transmission electron microscopy was used to observe the formation of VLPs. VLPs were formulated into an oil-adjuvanted maternal vaccine to evaluate humoral responses in breeding ducks via latex particle agglutination inhibition assay (LPAI) and microneutralization assay. The offspring were challenged with SBDSV to test the protective efficacy. A single dose of SBDSV was able to induce the high level of LPAI antibodies in ducks, with LPAI and neutralization peak titres of 4.9 ± 1.20 log2 and 7.1 ± 1.20 log2, respectively, at 4 weeks post-vaccination (wpv). The average LPAI titre of yolk antibodies in duck eggs receiving 2 doses (first and boost doses) of the vaccine was 5.3 ± 1.09 log2 at 4 weeks post-boost. The protective efficacy of the maternal vaccine was 87.5%–100%. These results indicate that SBDSV VLPs can be a promising vaccine candidate for controlling SBDS.

KW - Cherry Valley ducks

KW - duckling short beak and dwarfism syndrome

KW - protective immunity

KW - virus-like particle

U2 - 10.1111/tbed.14021

DO - 10.1111/tbed.14021

M3 - Journal article

VL - 69

SP - 570

EP - 578

JO - Transboundary and Emerging Diseases

JF - Transboundary and Emerging Diseases

SN - 1865-1674

IS - 2

ER -